ライフサイエンスコーパス: calcitonin

1 opressin, glucagon, parathyroid hormone, and calcitonin).

2 delta/notch-like EGF repeat containing; and calcitonin.

3 ure peptide as compared to undigested salmon calcitonin.

4 Alzheimer's amyloid-beta, human amylin, and calcitonin.

5 activation of the 1alpha(OH)ase promoter by calcitonin.

6 ction of small molecules relative to that of calcitonin.

7 Quantification of undigested salmon calcitonin, after solid-phase extraction from plasma, re

8 eful work-up, including measurement of serum calcitonin and carcinoembryonic antigen (and their doubl

9 al based on such prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling t

10 Calcitonin and carcinoembryonic antigen (CEA) doubling t

11 come of (18)F-FDG PET or (18)F-DOPA PET with calcitonin and CEA doubling times in 47 MTC patients.

12 Calcitonin and CEA levels correlated significantly with

13 separation, detection, and quantification of calcitonin and each of its precursors in human cancer ce

14 overy and characterization of O-glycosylated calcitonin and its analogous biosynthetic precursors.

15 he sequence from Asp(15) to Phe(19) of human calcitonin and reported as the minimal amyloidogenic mod

16 different therapeutic polypeptides; insulin, calcitonin, and exenatide across the monolayer.

17 Transport of insulin, calcitonin, and exenatide measured at different loading

18 es and clinical observations (eg, oestrogen, calcitonin, and teriparatide) or opportunistic repurposi

19 The expression of Samd9L was upregulated by calcitonin, and this was preceded by a significant incre

20 ion of a subset of TRA, parathyroid hormone, calcitonin, and thyroglobulin, as part of an effort to b

21 or 4, heart-type fatty acid binding protein, calcitonin, and tumor necrosis factor-related apoptosis-

22 ses, and persistently elevated postoperative calcitonin; and argue for the aggressive management of e

23 Calcitonin, another ligand of G-protein-coupled receptor

24 ata strongly suggest antiparallel beta-sheet calcitonin assembly, whereas modeling studies on the sho

25 de represents only partially the full-length calcitonin behavior.

26 complex with a truncated analogue of salmon calcitonin ([BrPhe(22)]sCT(8-32)) has been determined to

27 re the first to address the dynamics between calcitonin, C/EBPbeta, and SWI/SNF in the regulation of

28 The hormone calcitonin (CT) is primarily known for its pharmacologic

29 or (CTR) and the CTR-like receptor (CLR) for calcitonin (CT), amylin (Amy), calcitonin gene-related p

30 Although this VP-like effect of calcitonin diminished over the following 72 hours, the t

31 LDTg amylin receptors by the agonist salmon calcitonin dose-dependently reduces body weight, food in

32 lidate results from molecular simulations of calcitonin family peptides in aqueous solution.

33 amino-acid peptide hormone belonging to the calcitonin family, is an intrinsically disordered protei

34 D simulations to compare previously proposed calcitonin fibril structures.

35 or MTC in the United States with basal serum calcitonin for patients with thyroid nodules would cost

36 ar dynamics (MD) methods, finding that human calcitonin forms an alpha-helix.

37 ion induced by the Katp agonists cromakalim, calcitonin gene related peptide (CGRP) and the Kca agoni

38 mediating sensory neuropeptides galanin and calcitonin gene related peptide (CGRP) in a model of neu

39 The calcitonin gene related peptide (CGRP) pathway is import

40 increased labelling of neuronal profiles for calcitonin gene related peptide.

41 arch into the therapeutic potential of alpha-calcitonin gene-related peptide (alpha-CGRP) has been li

42 s, increased hippocampal expression of alpha calcitonin gene-related peptide (alphaCGRP) transcripts,

43 Intravenous alpha-calcitonin gene-related peptide (alphaCGRP)(8-37) produc

44 mouse bone induces a remarkable sprouting of calcitonin gene-related peptide (CGRP(+)) and neurofilam

45 Here, we report that calcitonin gene-related peptide (CGRP) activates CFTR-de

46 ing site of the homologous receptors for the calcitonin gene-related peptide (CGRP) and adrenomedulin

47 nables selective recognition of the peptides calcitonin gene-related peptide (CGRP) and adrenomedulli

48 ed receptors involved in energy homeostasis: calcitonin gene-related peptide (CGRP) and amylin recept

49 s for the treatment of acute migraine target calcitonin gene-related peptide (CGRP) and serotonin (5-

50 and/or ARs lead to release of neuropeptides calcitonin gene-related peptide (CGRP) and substance P (

51 expression of the potent vasoactive agents' calcitonin gene-related peptide (CGRP) and vascular endo

52 of asymmetric axosomatic synapses containing calcitonin gene-related peptide (CGRP) and vGluT2.

53 However, the A11 does contain dopamine and calcitonin gene-related peptide (CGRP) and, by this comb

54 ntibody and double stained with chicken anti-calcitonin gene-related peptide (CGRP) antibody.

55 ntly suppressed basal neuronal expression of calcitonin gene-related peptide (CGRP) as well as stimul

56 Calcitonin gene-related peptide (CGRP) evokes anxiety-li

57 The calcitonin gene-related peptide (CGRP) family of G prote

58 CIM0216 elicited the release of the peptides calcitonin gene-related peptide (CGRP) from sensory nerv

59 usion of neural factors, norepinephrine, and calcitonin gene-related peptide (CGRP) in denervated kid

60 y of evidence supports an important role for calcitonin gene-related peptide (CGRP) in migraine patho

61 Here, we show that neurons expressing calcitonin gene-related peptide (CGRP) in the parabrachi

62 In contrast with this, infusion of calcitonin gene-related peptide (CGRP) into BNST was rep

63 SIGNIFICANCE STATEMENT: The neuropeptide calcitonin gene-related peptide (CGRP) is a central play

64 Calcitonin gene-related peptide (CGRP) is a classic mole

65 The neuropeptide calcitonin gene-related peptide (CGRP) is a key player i

66 Calcitonin gene-related peptide (CGRP) is a neuropeptide

67 Calcitonin gene-related peptide (CGRP) is a potent arter

68 Calcitonin gene-related peptide (CGRP) is a potent neuro

69 Calcitonin gene-related peptide (CGRP) is a validated ta

70 The neuropeptide calcitonin gene-related peptide (CGRP) is associated wit

71 Calcitonin gene-related peptide (CGRP) is crucial in the

72 ed immunoabsorbent assay was used to measure calcitonin gene-related peptide (CGRP) levels in blood.

73 inase and estrogen receptor (CreER) into the calcitonin gene-related peptide (CGRP) locus that encode

74 very migraine patient.SIGNIFICANCE STATEMENT Calcitonin gene-related peptide (CGRP) monoclonal antibo

75 the contribution to cancer anorexia made by calcitonin gene-related peptide (CGRP) neurons in the pa

76 The calcitonin gene-related peptide (CGRP) pathway is a prom

77 The calcitonin gene-related peptide (CGRP) pathway is import

78 The neuropeptide calcitonin gene-related peptide (CGRP) plays a critical

79 Calcitonin gene-related peptide (CGRP) receptor antagoni

80 Calcitonin gene-related peptide (CGRP) receptor antagoni

81 X: an ultrapotent analog of capsaicin) and a calcitonin gene-related peptide (CGRP) receptor blocker

82 The calcitonin gene-related peptide (CGRP) receptor is a het

83 eover NO increased neuronal excitability and calcitonin gene-related peptide (CGRP) release and these

84 PA1-selective agonist, mustard oil (MO), for calcitonin gene-related peptide (CGRP) release from rat

85 idine (CLON) or their combination to inhibit calcitonin gene-related peptide (CGRP) release from spin

86 rmacologic inhibition of substance P (SP) or calcitonin gene-related peptide (CGRP) signaling in Vglu

87 pharmacological inhibition of substance P or calcitonin gene-related peptide (CGRP) signaling in Vglu

88 had no effect on acanthosis; restoration of calcitonin gene-related peptide (CGRP) signaling reverse

89 DCN A and C fibers and their relationship to calcitonin gene-related peptide (CGRP) staining in the d

90 Calcitonin gene-related peptide (CGRP) stimulated CLR en

91 s depend, in part, on its ability to release calcitonin gene-related peptide (CGRP) through an uniden

92 antibodies against VGLUT(1) , VGLUT(2) , and calcitonin gene-related peptide (CGRP) were used.

93 sal root ganglia (DRG), some neurons express calcitonin gene-related peptide (CGRP) without substance

94 y trigeminal nerve fibers immunoreactive for calcitonin gene-related peptide (CGRP), a marker for pol

95 that reacted with a labeled antibody against calcitonin gene-related peptide (CGRP), a marker of noci

96 tor (CLR) for calcitonin (CT), amylin (Amy), calcitonin gene-related peptide (CGRP), and adrenomedull

97 rves induced production of the neuropeptide, calcitonin gene-related peptide (CGRP), and CGRP treatme

98 ron somata, especially those also expressing calcitonin gene-related peptide (CGRP), and in central p

99 The relative numbers of neurons containing calcitonin gene-related peptide (CGRP), cocaine- and amp

100 ed transcript (cart), cholecystokinin (cck), calcitonin gene-related peptide (cgrp), galanin, hypocre

101 b, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investi

102 reactive (IR) for neurofilament 200 (N52) or calcitonin gene-related peptide (CGRP), or labeled by is

103 characterized by using six neuronal markers: calcitonin gene-related peptide (CGRP), substance P (SP)

104 ytochemical studies combined CTb with either calcitonin gene-related peptide (CGRP), substance P (SP)

105 did not colocalize with the C-fiber markers calcitonin gene-related peptide (CGRP), substance P, and

106 Calcitonin gene-related peptide (CGRP), the most abundan

107 n exists between migraine and release of the calcitonin gene-related peptide (CGRP), the possibility

108 the PBel neurons that respond to CO2 express calcitonin gene-related peptide (CGRP), we hypothesized

109 ological states, we injected the vasodilator calcitonin gene-related peptide (CGRP), which induces he

110 nerve fibers innervating taste buds contain calcitonin gene-related peptide (CGRP), which may be as

111 We show that a subset of adult calcitonin gene-related peptide (CGRP)-expressing myente

112 In contrast, calcitonin gene-related peptide (CGRP)-expressing neuron

113 Previously, we identified calcitonin gene-related peptide (CGRP)-expressing neuron

114 afferent neurons are almost exclusively non-calcitonin gene-related peptide (CGRP)-immunoreactive (-

115 ct contact with peripheral neurons secreting calcitonin gene-related peptide (CGRP).

116 in Old MAs along with impaired dilatation to calcitonin gene-related peptide (CGRP).

117 ophagus were removed, fixed, and stained for calcitonin gene-related peptide (CGRP).

118 of the membrane based on their expression of calcitonin gene-related peptide (CGRP).

119 and a population of cisplatin-activated lPBN calcitonin gene-related peptide (CGRP, a marker for glut

120 Gene expression of the neuropeptides calcitonin gene-related peptide (CGRP-alpha) and substan

121 hinly myelinated and unmyelinated fibers) or calcitonin gene-related peptide (CGRP; a marker more typ

122 ochemistry analysis using antibodies against calcitonin gene-related peptide (CGRP; sensory nerve fib

123 Microiontophoresis of calcitonin gene-related peptide 8-37 also showed a signi

124 related peptide and the receptor antagonists calcitonin gene-related peptide 8-37 and olcegepant on t

125 d and thin myelinated afferents labeled with calcitonin gene-related peptide and isolectin B4, and in

126 Many colocalize with calcitonin gene-related peptide and isolectin B4, and th

127 pression of mu opioid receptor and increased calcitonin gene-related peptide and substance P immunore

128 peptidergic nociceptive fibers (positive for calcitonin gene-related peptide and substance P) and mye

129 ther tested the effect of microiontophoresed calcitonin gene-related peptide and the receptor antagon

130 subset of sensory neurons that colabel with calcitonin gene-related peptide and TRPV1 suggestive of

131 assess the safety and efficacy of monoclonal calcitonin gene-related peptide antibodies for the preve

132 Variants of the calcitonin gene-related peptide artificially activate va

133 ADA reduces blood levels of the neuropeptide calcitonin gene-related peptide but increases the neurop

134 AMP-dependent secretion of IL-1beta and beta-calcitonin gene-related peptide by dendritic cells.

135 een confirmed, and the subsequent release of calcitonin gene-related peptide from a mouse heart has b

136 Calcitonin gene-related peptide immunolabeled (peptiderg

137 ated release of the neuropeptide transmitter calcitonin gene-related peptide in mouse DRG neurons.

138 evention and provide support for the role of calcitonin gene-related peptide in the pathogenesis of m

139 vascular activation, including expression of calcitonin gene-related peptide in the trigeminal gangli

140 The potent vasodilator calcitonin gene-related peptide mediates neurogenic infl

141 E11.5, followed by neurofilament-M neurons, calcitonin gene-related peptide neurons (peak cell cycle

142 Regenerated unmyelinated axons expressing calcitonin gene-related peptide project only to superfic

143 ibers were predominant (tyrosine hydroxylase/calcitonin gene-related peptide ratio 25.1 +/- 33.4; p <

144 ric synthesis of the major metabolite of the calcitonin gene-related peptide recepotor antagonist BMS

145 nputs and tested the effect of olcegepant, a calcitonin gene-related peptide receptor antagonist (1 m

146 While it has been demonstrated that calcitonin gene-related peptide receptor antagonists act

147 Calcitonin gene-related peptide receptor antagonists are

148 This is the first report on the efficacy of calcitonin gene-related peptide receptor antagonists at

149 pathway, showing that the central effects of calcitonin gene-related peptide receptor antagonists ext

150 uture non-vasoconstrictor approaches include calcitonin gene-related peptide receptor antagonists.

151 ore used to migraine, such as naproxen and a calcitonin gene-related peptide receptor inhibitor, olce

152 nucleus by specifically co-staining for the calcitonin gene-related peptide receptor subunits calcit

153 human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the preven

154 e presence of the components of a functional calcitonin gene-related peptide receptor, the calcitonin

155 ain G-protein-coupled receptors, such as the calcitonin gene-related peptide receptor, to the plasma

156 ng to demonstrate the presence of functional calcitonin gene-related peptide receptors in the ventrop

157 icin-evoked nocifensive responses, increased calcitonin gene-related peptide release from hindpaw ski

158 Acute infection activates calcitonin gene-related peptide sensory neurons coupled

159 ch, in return, allowed endoneurally released calcitonin gene-related peptide to pass through the nerv

160 As for sensory axons (immunostained for calcitonin gene-related peptide) in the urinary bladders

161 ng factor, thyrotropin-releasing hormone and calcitonin gene-related peptide) involved in the mediati

162 axons (peripherin-positive axons containing calcitonin gene-related peptide), without changes in sym

163 The expression of calcitonin gene-related peptide, a marker for peptidergi

164 omatostatin, gastric inhibitory polypeptide, calcitonin gene-related peptide, and adrenomedullin.

165 apsaicin measured by (Ca(2+))(i), release of calcitonin gene-related peptide, and inward currents.

166 e fly homolog of the vertebrate neuropeptide calcitonin gene-related peptide, as a circadian wake-pro

167 42, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention

168 nt differences were observed in substance P, calcitonin gene-related peptide, or neuropeptide Y prote

169 Calcitonin gene-related peptide, vesicular acetylcholine

170 modicum of investment, new targets, such as calcitonin gene-related peptide-based mechanisms, and en

171 born dopaminergic, GABAergic, nitrergic, and calcitonin gene-related peptide-expressing neurons and a

172 Here we identify calcitonin gene-related peptide-expressing neurons in th

173 dult mice, MET was restricted to a subset of calcitonin gene-related peptide-immunoreactive (IR) myen

174 Calcitonin gene-related peptide-immunoreactive sensory i

175 y, accompanied by increased axonal growth of calcitonin gene-related peptide-labeled fibers in the do

176 ased the density of PGP9.5-positive, but not calcitonin gene-related peptide-positive, free nerve end

177 ion of terminals within the VPMpc containing calcitonin gene-related peptide.

178 geted for anti-tyrosine hydroxylase and anti-calcitonin gene-related peptide.

179 matostatin, nefstatin-1, interleukin-11, and calcitonin gene-related peptide.

180 lar motoneurons, are also immunoreactive for calcitonin gene-related peptide.

181 sin I, SV2, or syntaxin and the neuropeptide calcitonin gene-related peptide.

182 staltic transmitters 5-hydroxytryptamine and calcitonin gene-related peptide; antagonists of these tr

183 mpanied by substantial increases of neuronal calcitonin gene-related polypeptide-alpha (CGRP) in both

184 l circuit for appetite suppression involving calcitonin gene-related protein (CGRP)-expressing PBN (C

185 Benefits of calcitonin-gene related peptide (CGRP) inhibition have n

186 The neuroactive peptide calcitonin-gene related peptide (CGRP) is known to act a

187 the lateral parabrachial nucleus (lPBN) and calcitonin-gene related peptide (CGRP) projections from

188 des vasoactive intestinal polypeptide (VIP), calcitonin-gene related peptide (CGRP), substance P (SP)

189 knowledge, between the internal dynamics of calcitonin-gene-related peptide (CGRP) and amylin (islet

190 Deletion or silencing of calcitonin-gene-related peptide alpha (alphaCGRP) gene e

191 and cOv are characterized with expression of calcitonin-gene-related peptide and cholecystokinin.

192 vation by icilin blocked capsaicin-triggered calcitonin-gene-related peptide release from colon tissu

193 onic levels of the inflammatory neuropeptide calcitonin-gene-related peptide, although inflammatory i

194 f rat spinal sensory afferents identified by Calcitonin-Gene-Related-Peptide (CGRP) for peptidergic t

195 sh-fixed and stained for immunoreactivity to calcitonin-gene-related-peptide (CGRP).

196 etrogradely labeled neurons from the DP were calcitonin-gene-related-peptide-positive (peptide-expres

197 This suggests that calcitonin has a potential therapeutic use in nephrogeni

198 While calcitonin has been used in therapy for osteoporosis and

199 rosis and Paget's disease for decades, human calcitonin (hCT) forms fibrils in aqueous solution that

200 o degradative release of encapsulated salmon calcitonin in gastric conditions while yielding rapid an

201 cription factor C/EBPbeta is up-regulated by calcitonin in kidney cells and results in a significant

202 igin of thyroid C cells, the major source of calcitonin in mammals and ancestors to neuroendocrine th

203 modeling complex was found to cooperate with calcitonin in the regulation of 1alpha(OH)ase.

204 Here, calcitonin increased intracellular cAMP and stimulated t

205 ining of rat kidney slices demonstrated that calcitonin induced a significant redistribution of AQP2

206 phosphorylation site on AQP2 both prevented calcitonin-induced membrane accumulation of AQP2.

207 Taken together, these data show that calcitonin induces cAMP-dependent AQP2 trafficking in co

208 and results in a significant enhancement of calcitonin induction of 1alpha(OH)ase transcription and

209 provide a mechanism, for the first time, for calcitonin induction of 1alpha(OH)ase.

210 Calcitonin is a 32-amino acid thyroid hormone that can f

211 Calcitonin is a 32-residue peptide hormone known for its

212 Calcitonin is a peptide hormone consisting of 32 amino a

213 The peptide hormone calcitonin is intimately connected with human cancer dev

214 he molecular mechanism of fiber formation by calcitonin is not well understood.

215 Fluorescence assays showed that calcitonin led to a 70% increase in exocytosis and a 20%

216 e relationship between the incremental serum calcitonin level before reoperation and the number of ly

217 This shows that the cellular calcitonin level is maintained to mitigate effects of bi

218 artment, and for an MTC with increased basal calcitonin level of 20-200 pg/ml (ipsilateral dissection

219 means of 5.3 vs 17.6 years) and having lower calcitonin levels (means of 115 vs 25,519 pg/mL), smalle

220 ary thyroid cancer (MTC) stratified by basal calcitonin levels before reoperation and the number of l

221 When serum calcitonin levels exceeded 1000 pg/mL before reoperation

222 ective CND based on preoperative basal serum calcitonin levels is an effective and safe alternative t

223 olvement, and in MTC with preoperative basal calcitonin levels more than 200 pg/ml (normal limit <10

224 With serum calcitonin levels of 1000 pg/mL or lower before reoperat

225 In 24 patients, serum calcitonin levels showed a 50% or greater decrease from

226 When serum calcitonin levels were 1000 pg/mL or lower before reoper

227 Immediate postoperative serum calcitonin levels were in the normal range (<5 pg/mL) in

228 by knowledge of specific exon mutations and calcitonin levels.

229 d based on specific exon mutations and serum calcitonin levels.

230 ate crosslinker, a small polypeptide (salmon calcitonin) loads and releases up to 45 mug/mg hydrogel

231 mic conditions, previous studies showed that calcitonin, not PTH, has an important role in the mainte

232 impact on DT (>/=100% increase of pre-pRAIT calcitonin or CEA DT or prolonged decrease of the biomar

233 nitiation of treatment with bisphosphonates, calcitonin, or raloxifene were treated as competing risk

234 two intrinsically disordered proteins of the calcitonin peptide family.

235 nd disordered aggregation in peptides of the calcitonin peptide family.

236 Medullary thyroid cancer arises from calcitonin-producing C-cells and accounts for 3-5% of al

237 ession and that amylin functions through the calcitonin receptor (CalcR) and receptor activity modify

238 The CAL-RAMP1 selectively activates the calcitonin receptor (CR), whereas, the CGRP-RAMP1 activa

239 selectivity of the class B G protein-coupled calcitonin receptor (CTR) and the CTR-like receptor (CLR

240 how that the core component of the AmyR, the calcitonin receptor (CTR), is expressed on VTA dopamine

241 Only chimeric constructs including the calcitonin receptor amino terminus exhibited responses t

242 /or alanine replacement of the region of the calcitonin receptor between residues 150 and 153 resulte

243 The crystal structure of the human calcitonin receptor ectodomain (CTR ECD) in complex with

244 region of the amino terminus of the Family B calcitonin receptor for agonist drug action.

245 Although calcitonin was able to activate the calcitonin receptor fully with the first 58 residues abs

246 or activity-modifying protein-1 (RAMP-1) and calcitonin receptor gene (CT-R) expression in striatum [

247 oclast marker genes NFATc1, cathepsin K, and calcitonin receptor in a RANKL-dependent manner, and con

248 consisting of 32 amino acid residues and the calcitonin receptor is a Class B G protein-coupled recep

249 The Family B G protein-coupled calcitonin receptor is an important drug target.

250 All compounds were full agonists at the calcitonin receptor with no activity at the secretin rec

251 In addition, Calcr (calcitonin receptor), which regulates osteoclast surviva

252 cture of a full-length class B receptor, the calcitonin receptor, in complex with peptide ligand and

253 Expression of RANK, TRAP, cathepsin K, calcitonin receptor, matrix metalloproteinase 9, NFATc1,

254 enomedullin (AM) and its receptor complexes, calcitonin receptor-like receptor (Calcrl) and receptor

255 get CGRP receptor, produced in part from the calcitonin receptor-like receptor (Calcrl) gene, has bee

256 , whereas, the CGRP-RAMP1 activates both the calcitonin receptor-like receptor (CLR) and CR.

257 Rs) is formed through the association of the calcitonin receptor-like receptor (CLR) and one of three

258 resence of CGRP and its receptor components, calcitonin receptor-like receptor (CLR) and receptor act

259 r is a heterodimer of two membrane proteins: calcitonin receptor-like receptor (CLR) and receptor act

260 pression and define cellular localization of calcitonin receptor-like receptor (CLR) and receptor act

261 Calcitonin receptor-like receptor (CLR) and the receptor

262 AM and its putative receptor calcitonin receptor-like receptor (CLR) are implicated i

263 ) with the G protein-coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) enables selectiv

264 e contribution of endosomal signaling of the calcitonin receptor-like receptor (CLR) to pain transmis

265 ization of a G protein-coupled receptor, the calcitonin receptor-like receptor (CLR), and receptor ac

266 ide mediates neurogenic inflammation via the calcitonin receptor-like receptor (CLR).

267 tonin gene-related peptide receptor subunits calcitonin receptor-like receptor and receptor activity

268 alcitonin gene-related peptide receptor, the calcitonin receptor-like receptor and the receptor activ

269 duce arterial differentiation in ECs via the calcitonin receptor-like receptor, thus revealing a surp

270 siological function of amylin binding to the calcitonin receptor.

271 tin immunoprecipitation analysis showed that calcitonin recruits C/EBPbeta to the 1alpha(OH)ase promo

272 Amylin is a calcitonin-related peptide co-secreted with insulin, whi

273 ndary visceral nucleus, which also expressed calcitonin-related polypeptide alpha (calca), a marker o

274 II afferents of two genes found in C-fibers: calcitonin-related polypeptide alpha (Calca/Cgrpalpha),

275 rs for fast motor neurons (Chondrolectin and calcitonin-related polypeptide alpha [Calca]), we analyz

276 that substantially change the proportions of calcitonin-related species released into the culture med

277 insertion into the disulfide bond of salmon calcitonin (sCT) demonstrates the utility for fluorescen

278 vitro, and absorption enhancement of salmon calcitonin (sCT) in vivo.

279 Salmon calcitonin (sCT) is a drug which has been shown to have

280 onjugation to the therapeutic peptide salmon calcitonin (sCT) via bridging of the Cys(1)-Cys(7) disul

281 sidues of both leucine enkephalin and salmon calcitonin (sCT) were targeted using appropriate diazoni

282 Reaction of salmon calcitonin (sCT) with 2,3-dibromomaleimide (1.1 excess)

283 ion of acylation of octreotide (Oct), salmon calcitonin (sCT), and human parathyroid hormone (hPTH) w

284 strate their capabilities in vivo for salmon calcitonin (sCT).

285 All three proteins bound salmon calcitonin (sCT).

286 interactions with the peptide hormone salmon calcitonin (sCT).

287 OS-1 cells expressing wild-type and chimeric calcitonin-secretin receptors.

288 a neuroendocrine cancer that originates from calcitonin-secreting parafollicular cells, or C cells.

289 for immuno-PET in relapsed MTC patients with calcitonin serum levels greater than 150 pg/mL.

290 a broad localization within the brain, while calcitonin, SIFamide, vasotocin, RGWamide, DLamide, FLam

291 ork, we first predict the structure of human calcitonin through two complementary molecular dynamics

292 Calcitonin-treated VP-deficient Brattleboro rats had a r

293 e tested in vitro with model proteins salmon calcitonin, urokinase, and rituximab to determine the ef

294 Although calcitonin was able to activate the calcitonin receptor

295 int disruption afforded by dexamethasone and calcitonin was established in comparison to the melanoco

296 l neck dissection was done only if the serum calcitonin was greater than 40 pg/mL.

297 P responses to four non-peptidyl ligands and calcitonin were studied in COS-1 cells expressing wild-t

298 ype II turn is the preferred conformation of calcitonin, whereas a type I turn is the preferred confo

299 al performance for the small peptide, salmon calcitonin, whereas lower crosslinking density of 1 mol%

300 ly investigated with a small protein, salmon calcitonin, which could be analyzed both without and wit